NapaJen Pharma is a clinical-stage, biopharmaceutical company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel therapeutics.
While nucleic acid-based drugs have demonstrated significant therapeutic potential, their efficient and targeted delivery has presented key challenges to drug developers. This is largely due to the high instability, low bioavailability and poor cellular uptake associated with oligonucleotides. NapaJen Pharma has developed a novel solution designed to overcome these delivery challenges. Our proprietary approach creates oligonucleotide therapeutics that bind directly to Dectin-1, a cell surface receptor expressed on antigen-presenting immune cells such as dendric cells or macrophages.
Furthermore, by leveraging our unique in-house platform technology, we can significantly reduce the time required for the identification of novel nucleic acid drug candidates.
Based on this unique delivery technology, NapaJen Pharma is enabling the development of its own internal drug candidates, as well as positioning itself as a partner-of-choice for biotechnology and pharmaceutical companies seeking to develop their own novel oligonucleotide therapeutics.

True Precision Medicine Meets Precision Delivery

By loading different oligo drugs onto its cell-specific drug delivery platform, NapaJen has made both
“precision-targeted immunosuppressive treatment” as well as “controlled immuno-stimulation” possible in preclinical models.

NapaJen^TM DDS

DDS：Drug Delivery System

Dendulation：

Precision Guided Immuno-therapeutics coupled with “Debdritic Cell Modulation”

Partnership

NapaJen Pharma’s oligonucleotide delivery platform provides broad opportunities to companies seeking solutions
for development of oligonucleotide therapeutics. These include:

• Collaboration to create new oligonucleotide therapeutics addressing target genes identified by partner companies
• Application of NapaJen Pharma’s nucleic acid delivery technology to oligonucleotide drug candidates being developed by partner companies

Partnering

• 2020-10-08
  news
  NapaJen Pharma Reports Positive Results from Phase 1 Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
• 2020-01-13
  news
  An article NapaJen was published in the January/February, 2020 issue of “Drug Development & Delivery”.
• 2019-11-30
  news
  Our website was renewed !
• 2019-11-08
  news
  Kenji Arima became a Director NapaJen Pharma, Inc.
• 2019-09-18
  news
  Kenji Arima became President at NapaJen Pharma Co., Ltd.
• 2019-08-02
  news
  Kenji Arima became CEO of NapaJen Pharma, Inc.
• 2019-03-18
  news
  NapaJen Pharma and Astellas Pharma Establish Research Collaboration